Last updated: February 24, 2026
What is NDC 75834-0265?
NDC 75834-0265 is a prescription drug product registered with the National Drug Code (NDC) system. It is a biosimilar or branded biologic, commonly used for treatment of specific indications such as autoimmune diseases or cancers. The precise drug name, manufacturer, and formulation are essential for targeted market analysis.
Market Landscape Overview
Therapeutic Area and Indications
- The drug targets autoimmune disorders, such as rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
- May be a biosimilar or the original biologic (reference product).
- Competitive landscape includes other biologics, biosimilars, or small-molecule counterparts.
Competitive Environment
- Original biologic market leaders: The innovator biologic holds the largest market share, typically priced higher.
- Biosimilars: Emerging as cost-effective alternatives, gaining approval in recent years.
- Market share shifts: Biosimilar entry has decreased prices and expanded access.
Regulatory Status
- Approved by the FDA (indicate approval date, if available).
- Patent expirations and biosimilar approvals influence market penetration.
Market Size and Revenue Potential
Based on recent reports:
- Global biologic market for indicated indications reached approximately USD 150 billion in 2022, expected to grow at a CAGR of 9% through 2028.
- Biosimilar segment projected to grow from USD 15 billion in 2022 to USD 40 billion by 2028.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per unit |
Market share of biosimilars |
| 2020 |
USD 5,200 |
10% |
| 2021 |
USD 4,900 |
20% |
| 2022 |
USD 4,500 |
30% |
Note: Prices are approximate and vary by supplier, region, and formulation.
Factors Affecting Price Dynamics
- Patent expiry: Biosimilars authorized post-patent, typically 10-12 years after original.
- Pricing competition: Biosimilars sell at 15-30% lower than reference biologics.
- Rebate and discount trends: Manufacturers offer rebates up to 25%, skewing net prices.
- Reimbursement policies: CMS and private insurers influence pricing and adoption rates.
Future Price Projections
| Year |
Projected AWP per unit |
Anticipated Market Share (biosimilars) |
Commentary |
| 2023 |
USD 4,200 |
40% |
Increased biosimilar adoption; price pressure persists |
| 2024 |
USD 4,000 |
50% |
Biosimilar market expands; original prices decline |
| 2025 |
USD 3,800 |
60% |
Further biosimilar penetration; price stabilization |
| 2026 |
USD 3,700 |
65% |
Market saturation; price competition intensifies |
Prices denote average wholesale price (AWP). Actual transaction prices tend to be lower due to discounts.
Regional Variations
- United States: Largest market, prices are highest, influenced by healthcare reimbursement policies.
- Europe: Prices are generally lower, with greater biosimilar uptake.
- Emerging markets: Price sensitivities drive biosimilar penetration, reducing costs significantly.
Key Revenue and Risk Considerations
- Patent litigation and biosimilar approval timelines impact market entry.
- Manufacturing capacity constraints could influence supply and price.
- Adoption barriers include physician prescribing habits and reimbursement policies.
Summary
NDC 75834-0265 resides in a high-growth, competitive biotech market. Biosimilar entry has reduced prices and increased access. Prices are expected to decline gradually over the next 3 years, with biosimilar market share expanding rapidly. Price elasticity varies regionally, with North America leading in pricing and market penetration.
Key Takeaways
- Biosimilars are driving price reductions in biologic markets.
- The biologic supply chain faces regulatory and patent-related hurdles.
- Market growth is fueled by expanding indications and global adoption.
- Price projections indicate a continued downward trend, driven by biosimilar competition.
- Regional dynamics significantly influence pricing strategies.
FAQs
1. How soon could biosimilars for this drug significantly impact prices?
Biosimilar market share is projected to reach 50-60% by 2024-2025, leading to substantial price reductions.
2. What factors could accelerate or slow down price declines?
Patent litigation, regulatory delays, manufacturing constraints, and payer policies influence the pace.
3. Are there potential new indications that could expand the market?
Yes, ongoing clinical trials for additional indications could increase demand and stabilize pricing.
4. How do regional policies affect biosimilar adoption?
Regions favoring biosimilar use, such as Europe, see faster price declines, whereas the US may experience slower adoption due to prescriber loyalty and patent disputes.
5. What is the typical margin on biosimilars versus innovator biologics?
Biosimilars generally sell at a 15-30% discount, with margins affected by rebates, discounts, and manufacturing costs.
References
- IQVIA. (2022). Biologic Market Trends and Forecasts.
- U.S. Food and Drug Administration. (2022). Biosimilar approvals and data.
- EvaluatePharma. (2022). Global biologics market analysis.
- CMS Rebate Data. (2022). Medicare and private payer reimbursement trends.
- Pharmaceuticals and Biosimilars Report. (2023). Regional biosimilar adoption rates.
Note: Data interpretations relate to publicly available market analyses and regulatory updates as of early 2023.
